Sonora Investment Management Group LLC acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,448 shares of the company's stock, valued at approximately $518,000.
A number of other large investors also recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in shares of Harrow in the third quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. increased its position in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after acquiring an additional 227 shares during the period. Hills Bank & Trust Co bought a new stake in Harrow during the 3rd quarter valued at $107,000. Huntington National Bank acquired a new position in Harrow during the 3rd quarter worth $164,000. Finally, Clarus Group Inc. bought a new position in shares of Harrow in the third quarter worth $225,000. Institutional investors own 72.76% of the company's stock.
Harrow Price Performance
Shares of HROW stock traded up $0.89 during mid-day trading on Tuesday, hitting $30.72. 210,432 shares of the stock traded hands, compared to its average volume of 328,838. Harrow, Inc. has a twelve month low of $9.13 and a twelve month high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company's 50-day simple moving average is $35.93 and its 200-day simple moving average is $39.62. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -32.71 and a beta of 0.69.
Wall Street Analysts Forecast Growth
Separately, B. Riley reduced their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th.
Check Out Our Latest Stock Analysis on HROW
Harrow Company Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Stories
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
